Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
Gemcitabine-based chemotherapy is the current standard treatment for biliary tract cancers (BTCs) and resistance to gemcitabine remains the clinical challenge. <i>TP53</i> mutation has been shown to be associated with poor clinicopathologic characteristics and survival in patients with BTCs, indicat...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI AG
2020-10-01
|
| Colección: | Biomolecules |
| Materias: | |
| Acceso en línea: | https://www.mdpi.com/2218-273X/10/11/1474 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|